Ipsos’ Oncology Molecular Diagnostics Portfolio Expands to China
The Lab Mapping Study – already launched in the US, EU5 and Australia – surveys a large number of Laboratory Directors / Managers to gain insights into: the resource allocation of labs involved with oncology biomarker testing, access to various types and brands of molecular diagnostics platforms, biomarker testing volume, cancer sample flow between different types of hospital and commercial laboratories, barriers and drivers around insourcing and outsourcing of biomarker testing, and the current and future use of Next Generation Sequencing in these laboratories. Crucially for China, the flow of samples both within and between provinces, as well as to other countries, will be mapped. The study will also help identify the laboratories that are considered to be the top commercial and non-commercial labs for oncology biomarker testing in the country.
The Oncology MDx Monitor complements the Lab Mapping Study by adding the viewpoint of cancer-treating physicians and pathologists, and collecting Real World Evidence on how individual cancer patients and biopsy samples are being tested in the clinical setting (based on de-identified patient and sample record forms). This includes a detailed look at the types of biopsies used, the split by methodology and test brand for each of the biomarkers tested, turn-around time and testing location, as well as the drivers for and barriers to individual biomarker tests. For this initial wave of the study, the focus will be on non-small cell lung cancer, with other cancer types to be added in future waves of the research.
Commented Pieter De Richter, Head of Ipsos Healthcare’s Real World Evidence Portfolio in Asia Pacific, Middle East & North Africa:
‘Ipsos’ MDx studies reveal a rapidly changing biomarker testing landscape in Oncology around the world. With the expansion of these studies to China, pharmaceutical companies and molecular diagnostics manufacturers will be able to gain a comprehensive insight into how these changes are impacting this key Asian market. The Lab Mapping Study and MDx Monitor provide a multi-stakeholder view of the very complex and highly heterogeneous laboratory landscape across a range of major cities in China, crucial for any company planning to expand the use of their biomarker-associated anti-cancer drug, preparing to launch a new oncology test kit or biomarker testing solution, or gauging the opportunities and challenges that exist in the important growth market. ’
Contact:
• Pieter De Richter, Head of Syndicated Real World Evidence, APAC & MENA
Tel: +601 2290 0315; Email: [email protected]
• Joanna Butcher, Syndicated Marketing Communications Director
Tel: +44 (0)7818 422117; Email: [email protected]
About Healthcare Service Line
At Ipsos we are passionately curious about people, markets, brands and society. We make our changing world easier and faster to navigate and inspire clients to make smarter decisions. Our Healthcare Service Line partners with pharmaceutical, bio-tech and medical device manufacturers to inspire better healthcare. Operating in over 40 countries, our 700+ healthcare experts support key business decisions for our clients throughout the commercial lifecycle.
